These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26461817)

  • 21. Ustekinumab (Stelara) for psoriasis.
    Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
    [No Abstract]   [Full Text] [Related]  

  • 22. [The biological treatments for moderate to severe plaque psoriasis].
    Thielen AM; Marazza G
    Rev Med Suisse; 2008 Apr; 4(155):1089-90, 1092-4. PubMed ID: 18610721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis Area and Severity Index 75 rate of classical inpatient dithranol therapy under daily life conditions.
    Painsi C; Patscheider M; Inzinger M; Huegel R; Lange-Asschenfeldt B; Quehenberger F; Wolf P
    Br J Dermatol; 2015 Sep; 173(3):815-7. PubMed ID: 25704591
    [No Abstract]   [Full Text] [Related]  

  • 24. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis.
    Bigby M
    Arch Dermatol; 2004 Mar; 140(3):347-8. PubMed ID: 15023778
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 28. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 29. Calcipotriene for psoriasis.
    Med Lett Drugs Ther; 1994 Aug; 36(928):70-1. PubMed ID: 8035754
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Pich J
    Int J Evid Based Healthc; 2019 Sep; 17(3):187-188. PubMed ID: 31162273
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment.
    Famenini S; Wu JJ
    Cutis; 2013 Sep; 92(3):140-7. PubMed ID: 24153143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
    Brunasso AM; Puntoni M; Delfino C; Massone C
    Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparative efficacy of biologics in psoriasis: a review.
    Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
    Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis for seniors.
    Weinberg JM
    Cutis; 2016 Feb; 97(2):83. PubMed ID: 26919496
    [No Abstract]   [Full Text] [Related]  

  • 37. Topical tazarotene vs. coal tar in stable plaque psoriasis.
    Kumar U; Kaur I; Dogra S; De D; Kumar B
    Clin Exp Dermatol; 2010 Jul; 35(5):482-6. PubMed ID: 19874376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

  • 39. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.